Maravai LifeSciences completes acquisition of DNA and RNA Business from Officinae Bio to advance drug development capabilities
Acquiring Company
Maravai LifeSciences
Acquired Company
Officinae Bio
San Diego
VeniceBiotechnologyHealth CareBiotechnologyTherapeuticsDescription
Maravai LifeSciences, Inc. has successfully completed the acquisition of the DNA and RNA business from Officinae Bio. This strategic move integrates the AI-driven mRNA design platforms of Officinae Bio with the leading capabilities of Maravai and TriLink BioTechnologies in drug manufacturing, providing customers with comprehensive expertise and innovative technologies to expedite progress from mRNA sequence optimization to clinical trials and commercial production. The acquisition also signifies Maravai's entry into the important European market, enhancing its production presence and driving growth in multiple product lines post-pandemic.
Quick answer
Maravai LifeSciences is acquiring Officinae Bio, announced February 24, 2025. Maravai LifeSciences is based in San Diego, California, United States.
- How much did Maravai LifeSciences pay for Officinae Bio?
- The deal value was not disclosed.
- What does Maravai LifeSciences do?
- Maravai LifeSciences is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines, and to support research on human diseases.
- Where are Maravai LifeSciences and Officinae Bio based?
- Maravai LifeSciences is based in San Diego, California, United States. Officinae Bio is based in Venice, Veneto, Italy.
- Who are the decision-makers at Maravai LifeSciences?
- Fundz holds 1 contact at Maravai LifeSciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie acquires Cerevel Therapeutics for $45 per share (March 31, 2025)
- BioNTech completes acquisition of Biotheus to strengthen oncology strategy (February 4, 2025)
- Exicure, Inc. completes acquisition of GPCR Therapeutics USA Inc. to enhance its pipeline for cell and gene therapies (January 22, 2025)
- Novartis completes acquisition of Anthos Therapeutics (April 4, 2025)
- Novartis acquires Anthos Therapeutics for $3.1B, $3.1B (April 3, 2025)
- GSK completes acquisition of IDRx, Inc. to enhance precision therapeutics for treating gastrointestinal stromal tumours (February 24, 2025)
Who to call at Maravai LifeSciences, and when
When Maravai LifeSciences changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Maravai LifeSciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Maravai LifeSciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Maravai LifeSciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Maravai LifeSciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Officinae Bio?
Officinae Bio was acquired by Maravai LifeSciences, based in San Diego. The deal was reported on February 24, 2025. Maravai LifeSciences is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines, and to support research on human diseases. Maravai LifeSciences is publicly traded (MRVI) and operates in Biotechnology.
When did Maravai LifeSciences acquire Officinae Bio?
Maravai LifeSciences's acquisition of Officinae Bio was reported on February 24, 2025. Maravai LifeSciences, Inc. has successfully completed the acquisition of the DNA and RNA business from Officinae Bio. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Officinae Bio do?
Officinae Bio is a privately held technology company based in Venice, Italy, with a proprietary digital platform to support the biological design of therapeutics. It is privately held, operating in Biotechnology, and is based in Venice.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.